Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Repligen Corp (RGEN)

Repligen Corp (RGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,330,796
  • Shares Outstanding, K 56,291
  • Annual Sales, $ 634,440 K
  • Annual Income, $ -25,510 K
  • EBIT $ 10 M
  • EBITDA $ 95 M
  • 60-Month Beta 1.11
  • Price/Sales 14.77
  • Price/Cash Flow 53.12
  • Price/Book 4.46

Options Overview Details

View History
  • Implied Volatility 41.60% (+0.50%)
  • Historical Volatility 41.68%
  • IV Percentile 11%
  • IV Rank 11.57%
  • IV High 84.92% on 04/07/25
  • IV Low 35.94% on 08/14/25
  • Expected Move (DTE 14) 10.35 (6.25%)
  • Put/Call Vol Ratio 2.88
  • Today's Volume 167
  • Volume Avg (30-Day) 137
  • Put/Call OI Ratio 2.88
  • Today's Open Interest 14,348
  • Open Int (30-Day) 12,860
  • Expected Range 155.41 to 176.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.44
  • Number of Estimates 5
  • High Estimate 0.46
  • Low Estimate 0.43
  • Prior Year 0.44
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
139.40 +19.08%
on 11/07/25
174.01 -4.60%
on 11/28/25
+20.16 (+13.82%)
since 11/05/25
3-Month
112.73 +47.25%
on 09/15/25
174.01 -4.60%
on 11/28/25
+41.44 (+33.27%)
since 09/05/25
52-Week
102.96 +61.23%
on 04/07/25
182.52 -9.05%
on 01/28/25
+23.74 (+16.69%)
since 12/05/24

Most Recent Stories

More News
Repligen Corporation to Present at Evercore Healthcare Conference

WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participate...

RGEN : 165.77 (+0.01%)
Why Repligen (RGEN) Stock Is Trading Up Today

Why Repligen (RGEN) Stock Is Trading Up Today

RGEN : 165.77 (+0.01%)
Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know

Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know

ENOV : 28.05 (+0.32%)
CORT : 84.57 (-0.11%)
LNTH : 62.23 (+0.58%)
EVH : 4.02 (+0.25%)
RGEN : 165.77 (+0.01%)
3 Cash-Producing Stocks We Approach with Caution

3 Cash-Producing Stocks We Approach with Caution

RGEN : 165.77 (+0.01%)
PCTY : 146.30 (-0.16%)
IQV : 222.63 (-1.02%)
Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN)

Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN)

RGEN : 165.77 (+0.01%)
Repligen Corporation to Present at Upcoming November Conferences

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending...

RGEN : 165.77 (+0.01%)
5 Revealing Analyst Questions From Repligen’s Q3 Earnings Call

5 Revealing Analyst Questions From Repligen’s Q3 Earnings Call

RGEN : 165.77 (+0.01%)
3 Hyped Up Stocks with Open Questions

3 Hyped Up Stocks with Open Questions

VLY : 11.48 (-0.35%)
GOLF : 84.31 (+0.76%)
RGEN : 165.77 (+0.01%)
RGEN Q3 Deep Dive: Robust Product Demand Offset by Margin Pressures and Guidance Reset

RGEN Q3 Deep Dive: Robust Product Demand Offset by Margin Pressures and Guidance Reset

RGEN : 165.77 (+0.01%)
Why Repligen (RGEN) Shares Are Trading Lower Today

Why Repligen (RGEN) Shares Are Trading Lower Today

RGEN : 165.77 (+0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the...

See More

Key Turning Points

3rd Resistance Point 174.40
2nd Resistance Point 171.04
1st Resistance Point 168.40
Last Price 165.77
1st Support Level 162.39
2nd Support Level 159.03
3rd Support Level 156.39

See More

52-Week High 182.52
Last Price 165.77
Fibonacci 61.8% 152.13
Fibonacci 50% 142.74
Fibonacci 38.2% 133.35
52-Week Low 102.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar